Axogen to acquire BioCircuit Technologies for $200 million

Axogen, Inc. announced a definitive agreement to acquire BioCircuit Technologies, Inc. for $200 million in cash. The acquisition adds NerveTape, the first FDA-approved device for sutureless peripheral nerve repair, and is expected to close in Q4 2026.

“Axogen will acquire BioCircuit for total consideration of $200 million in cash at closing.”ir.axogeninc.com

• 2 sources
• ir.axogeninc.comAxogen Enters into Definitive Agreement to Acquire BioCircuit Technologies :: Axogen, Inc. (AXGN)Sep 10, 2026
• morningstar.comAxogen Enters into Definitive Agreement to Acquire BioCircuit Technologies | MorningstarSep 10, 2026

Summarized from public sources; check the original articles before acting on it.